Skip to main content
. 2022 Apr 22;17(4):e0266707. doi: 10.1371/journal.pone.0266707

Fig 4. Overall survival (OS) rates of patients who received HAIC (HAIC cohort) vs. standard chemotherapy (standard chemotherapy cohort).

Fig 4

Since the tumors were determined to be refractory to GC therapy, the OS rates were 58.3% and 35.1% at 6 months and 35.0% and 8.8% at 1 year for the HAIC and standard chemotherapy cohorts, respectively. The median OS after being refractory to GC was 6.3 months (95% confidence interval [CI] 2.97–9.56) and 3.7 months (95% CI 1.87–5.60), respectively. The OS of the HAIC cohort was better than that of the standard chemotherapy cohort (P = 0.045). Since disease onset, the OS rates were 67.5% and 30.6% at 1 year and 40.5% and 0% at 2 years, respectively. The median OS after the disease onset was 19.7 months (95% CI 9.84–29.6) and 10.8 months (95% CI 8.36–13.2), respectively. The OS of the HAIC cohort was better that of the standard chemotherapy cohort since the disease onset (P = 0.006).